Why XENE fell 26.8% on Sep 18 2026: clinical trial pause
XENE-26.8%on Fri Sep 18 2026
Xenon Pharmaceuticals Inc was down 26.8% on the day at $42.00, ranked #3 on 192× its usual five-minute volume, when TapeRank recorded this drop at 06:41 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 06:41 ETMOVER · PRE-MARKET
$42.00 · ▼ 26.8% ON THE DAY · 192× 5M RVOL · RANK #3
JUSTIFIEDCONFIDENCE5/5XENE is down 26.8% to $42 pre-market after Xenon paused enrollment in ongoing depression studies following neuropsychiatric adverse events. The pause directly threatens the psychiatry development timeline and materially outweighs the positive NDA and enrollment updates reported alongside it.
WHYA 26.8% selloff is proportionate to a safety-related clinical-trial enrollment pause that can delay or impair a major pipeline program.ANALYZED 07:08 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 06:41 ET
LAST42.00DAY▼ 26.8%5 MIN▼ 0.31%5M RVOL192×5M $VOL$1.0MFLOAT*96.7MRANK#3SESSIONPRE-MARKETVWAP41.97HOD42.50LOD41.06OR HIGH—OR LOW—PREV CLOSE57.35PM HIGH42.50PM LOW41.06GAP▼ 26.77% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $44.02, -23.2% on the previous close of $57.35
- 09:30 ETRegular-session high, $44.85
- 15:53 ETRegular-session low, $39.08
- 15:59 ETLast trade of the regular session, $39.74, -30.7% on the previous close of $57.35
- Volume: 16.3M shares in regular hours, 852K before the open
XENE opened at $44.02 after trading at $42.00 pre-market, briefly reached $44.85, and then declined through the session to a low of $39.08 before ending at $39.74. There were no halts, and TapeRank's read tied the move to Xenon's temporary pause of enrollment in ongoing psychiatry studies after neuropsychiatric adverse events, which overshadowed the company’s NDA submission for azetukalner and progress toward X-NOVA2 enrollment. The stock finished 30.7% below the previous close of $57.35.
WRITTEN THU OCT 15 2026 17:52 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 02:04 ETXenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's WhyBenzinga
- THU 16:05 ETXenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain ActiveBenzinga
- THU 16:05 ETXenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027Benzinga
- THU 16:02 ETXenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDABenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list